FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval ... Read More
Zydus Lifesciences, Daewoong Pharmaceutical forge US market alliance for Leuprolide Acetate
Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd., and South Korea's Daewoong Pharmaceutical Co., Ltd. have entered into a significant exclusive licensing agreement. ... Read More
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This ... Read More
AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and early-stage clinical assets across a host of ... Read More
Caplin Point to tap into $35m market after FDA approval for NIMBEX generic
Caplin Steriles, a subsidiary of India's Caplin Point Laboratories, has obtained final approval from the US Food and Drug Administration (FDA) for its generic version ... Read More
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration (FDA) for the treatment of relapsed or ... Read More
AbbVie bags RINVOQ FDA approval for nr-axSpA in adults
RINVOQ FDA approval for nr-axSpA : AbbVie has bagged approval for its selective JAK inhibitor RINVOQ (upadacitinib 15 mg, once daily) from the US Food ... Read More
AbbVie acquires UK biotech company DJS Antibodies for $255m
AbbVie has acquired DJS Antibodies, a privately-held UK-based biotech company, in an all-cash transaction valued at approximately $255 million, in a move to further strengthen ... Read More